[
  {
    "Column": "record",
    "Description": "record: Record number",
    "Answer_Options": "NA"
  },
  {
    "Column": "uuid",
    "Description": "uuid: Participant identifier",
    "Answer_Options": "NA"
  },
  {
    "Column": "date",
    "Description": "date: Completion time and date",
    "Answer_Options": "NA"
  },
  {
    "Column": "status",
    "Description": "status: Participant status",
    "Answer_Options": "1=Terminated,2=Overquota,3=Qualified,4=Partial"
  },
  {
    "Column": "S1",
    "Description": "S1: You are about to enter a market research survey. We are being asked to pass on to our client details of adverse events about individual patients or groups of patients and / or product complaints that are raised during the course of market research sur",
    "Answer_Options": "1=I would like to proceed and protect my identity,2=I would like to proceed and give permission for my contact details to be passed on to the Drug Safety department of the,3=I don’t want to proceed"
  },
  {
    "Column": "S2b",
    "Description": "S2b: What is your primary role?",
    "Answer_Options": "1=Physician,2=Nurse Practitioner,3=Physician’s Assistant,99=Other"
  },
  {
    "Column": "S2",
    "Description": "S2: What is your primary specialty?",
    "Answer_Options": "1=Cardiologist,2=Internal Medicine / General Practitioner / Primary Care / Family Practice,3=Nephrologist,4=Endocrinologist,5=Lipidologist,6=Nurse Practitioner,7=Physician’s Assistant,99=Other"
  },
  {
    "Column": "S2a",
    "Description": "S2a: In what type of doctor’s office do you work?",
    "Answer_Options": "1=Cardiologist,2=Internal Medicine / General Practitioner / Primary Care / Family Practice,3=Other"
  },
  {
    "Column": "qCARD_SPECIALTY",
    "Description": "qCARD_SPECIALTY: CARD SPECIALTY",
    "Answer_Options": "1=CARD,2=NEPH/ENDO/LIP"
  },
  {
    "Column": "qSPECIALTY",
    "Description": "qSPECIALTY: SPECIALTY",
    "Answer_Options": "1=CARD,2=PCP,3=NPPA"
  },
  {
    "Column": "S3a",
    "Description": "S3a: What type of Cardiologist are you primarily?",
    "Answer_Options": "1=Interventional Cardiologist,2=General Cardiologist,3=Preventative Cardiologist"
  },
  {
    "Column": "qTYPE_OF_CARD",
    "Description": "qTYPE_OF_CARD: TYPE OF CARD",
    "Answer_Options": "1=Interventional Card,2=General Card,3=Preventative Card"
  },
  {
    "Column": "qON_LIST_OFF_LIST",
    "Description": "qON_LIST_OFF_LIST: ON-LIST/OFF-LIST",
    "Answer_Options": "1=CARD ON-LIST,2=CARD OFF-LIST,3=PCP ON-LIST,4=PCP OFF-LIST,5=NPPA ON-LIST,6=NPPA OFF-LIST"
  },
  {
    "Column": "qLIST_TIER",
    "Description": "qLIST_TIER: LIST TIER",
    "Answer_Options": "1=TIER 1,2=TIER 2,3=TIER 3,4=TIER 4"
  },
  {
    "Column": "qLIST_PRIORITY_ACCOUNT",
    "Description": "qLIST_PRIORITY_ACCOUNT: LIST PRIORITY ACCOUNT",
    "Answer_Options": "1=PRIORITY,2=NOT PRIORITY"
  },
  {
    "Column": "S4",
    "Description": "S4: Are you currently board certified or eligible in your specialty?",
    "Answer_Options": "1=Board Eligible,2=Board Certified,3=Neither"
  },
  {
    "Column": "S5r1",
    "Description": "S5r1: Advertising Agency - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Advertising Agency,1=Advertising Agency",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r2",
    "Description": "S5r2: Marketing/Market Research Firm - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Marketing/Market Research Firm,1=Marketing/Market Research Firm",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r3",
    "Description": "S5r3: Public Relations Firm - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Public Relations Firm,1=Public Relations Firm",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r4",
    "Description": "S5r4: Any media company (Print, Radio, TV, Internet) - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Any media company (Print, Radio, TV, Internet),1=Any media company (Print, Radio, TV, Internet)",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r5",
    "Description": "S5r5: Pharmaceutical Drug / Device Manufacturer (outside of clinical trials) - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Pharmaceutical Drug / Device Manufacturer (outside of clinical trials),1=Pharmaceutical Drug / Device Manufacturer (outside of clinical trials)",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r6",
    "Description": "S5r6: Governmental Regulatory Agency (e.g., Food & Drug Administration (FDA)) - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: Governmental Regulatory Agency (e.g., Food & Drug Administration (FDA)),1=Governmental Regulatory Agency (e.g., Food & Drug Administration (FDA))",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S5r7",
    "Description": "S5r7: None of these - Are you or is any member of your family currently employed by, or have a commercial affiliation with any of the following?",
    "Answer_Options": "0=NO TO: None of these,1=None of these",
    "ParentQuestion": "S5"
  },
  {
    "Column": "S6",
    "Description": "S6: How many years have you been in clinical practice, post residency/training?",
    "Answer_Options": "NA"
  },
  {
    "Column": "S7",
    "Description": "S7: And to confirm, are you currently practicing full-time (i.e. 40+ hours weekly across all settings) or part-time?",
    "Answer_Options": "1=Full-Time,2=Part-Time"
  },
  {
    "Column": "S8r1",
    "Description": "S8r1: Treating/Managing patients - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r2",
    "Description": "S8r2: Performing academic functions (e.g., teaching, publishing) - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r3",
    "Description": "S8r3: Participating in clinical research - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S8r4",
    "Description": "S8r4: Performing other functions - Approximately what percentage of your professional time is spent performing each of the following activities?",
    "Answer_Options": "NA",
    "ParentQuestion": "S8"
  },
  {
    "Column": "S9",
    "Description": "S9: Which of the following best represents the setting in which you spend most of your professional time?",
    "Answer_Options": "1=Private Solo Practice,2=Private Group Practice,3=Multi-specialty Practice / Comprehensive Care,4=Staff HMO,5=Community Hospital,6=Academic/University Hospital,7=VA Hospital,8=None of the above"
  },
  {
    "Column": "S10",
    "Description": "S10: Using your best estimate, how many adult patients, age 18 or older, do you personally manage in your practice in a month? By ‘personally’, we mean patients for whom you are a primary treatment decision maker.",
    "Answer_Options": "NA"
  },
  {
    "Column": "S11",
    "Description": "S11: Of those adult patients for whom you are the primary treatment decision maker, roughly how many have a confirmed diagnosis of hypercholesterolemia with established cardiovascular disease (CVD)?",
    "Answer_Options": "NA"
  },
  {
    "Column": "S12r1",
    "Description": "S12r1: Over 5 years ago - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r2",
    "Description": "S12r2: Within the last 3-5 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r3",
    "Description": "S12r3: Within the last 1-2 years - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12"
  },
  {
    "Column": "S12r4",
    "Description": "S12r4: Within the last year - Of those, how many patients have had an event (MI, CAD, coronary revascularization, stent placement, etc.) …",
    "Answer_Options": "NA",
    "ParentQuestion": "S12"
  },
  {
    "Column": "A1r1",
    "Description": "A1r1: Leqvio (inclisiran) - To the best of your knowledge, which statement below best describes the current indication for each of the following treatments?",
    "Answer_Options": "1=As an adjunct to diet, alone or in combination with other LDL-C-lowering therapies, in adults with primary hyperlipidemi,2=As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia",
    "ParentQuestion": "A1"
  },
  {
    "Column": "A1r2",
    "Description": "A1r2: Praluent (alirocumab) - To the best of your knowledge, which statement below best describes the current indication for each of the following treatments?",
    "Answer_Options": "1=As an adjunct to diet, alone or in combination with other LDL-C-lowering therapies, in adults with primary hyperlipidemi,2=As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia",
    "ParentQuestion": "A1"
  },
  {
    "Column": "A1r3",
    "Description": "A1r3: Repatha (evolocumab) - To the best of your knowledge, which statement below best describes the current indication for each of the following treatments?",
    "Answer_Options": "1=As an adjunct to diet, alone or in combination with other LDL-C-lowering therapies, in adults with primary hyperlipidemi,2=As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia",
    "ParentQuestion": "A1"
  },
  {
    "Column": "A1r4",
    "Description": "A1r4: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - To the best of your knowledge, which statement below best describes the current indication for each of the following treatments?",
    "Answer_Options": "1=As an adjunct to diet, alone or in combination with other LDL-C-lowering therapies, in adults with primary hyperlipidemi,2=As an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia",
    "ParentQuestion": "A1"
  },
  {
    "Column": "A2a",
    "Description": "A2a: To the best of your knowledge, which of the following best describes the current post-ACS guideline recommendation regarding lipid-lowering?",
    "Answer_Options": "1=Recommend a non-statin lipid-lowering agent for patients on maximally tolerated statins with LDL-C levels ≥55 mg/dL,2=Recommend a non-statin lipid-lowering agent for patients on maximally tolerated statins with LDL-C levels ≥70 mg/dL,3=Recommend a non-statin lipid-lowering agent for patients on maximally tolerated statins with LDL-C levels ≥100 mg/dL"
  },
  {
    "Column": "A2b",
    "Description": "A2b: And to the best of your knowledge, which of the following best describes the current post-ACS guideline recommendation specific to lipid-lowering therapy?",
    "Answer_Options": "1=Recommend a statin first, add or switch to ezetimibe if needed, then add or switch to a PCSK9i if needed,2=Recommend a statin + ezetimibe first, add or switch to a PCSK9i if needed,3=Recommend a PCSK9i first"
  },
  {
    "Column": "A3r1",
    "Description": "A3r1: Statin only (i.e., no additional therapy) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r2",
    "Description": "A3r2: Leqvio (inclisiran) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r3",
    "Description": "A3r3: Praluent (alirocumab) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r4",
    "Description": "A3r4: Repatha (evolocumab) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r5",
    "Description": "A3r5: Zetia (ezetimibe) or generic ezetimibe - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r6",
    "Description": "A3r6: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3r7",
    "Description": "A3r7: Other - For your LAST 100 [res PatientHoverover] with uncontrolled LDL-C, please indicate for how many you prescribed each of the following therapies?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3"
  },
  {
    "Column": "A3ar1c1",
    "Description": "A3ar1c1: In addition to statin - Leqvio (inclisiran) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar1c2",
    "Description": "A3ar1c2: Without a statin - Leqvio (inclisiran) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar2c1",
    "Description": "A3ar2c1: In addition to statin - Praluent (alirocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar2c2",
    "Description": "A3ar2c2: Without a statin - Praluent (alirocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar3c1",
    "Description": "A3ar3c1: In addition to statin - Repatha (evolocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar3c2",
    "Description": "A3ar3c2: Without a statin - Repatha (evolocumab) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar4c1",
    "Description": "A3ar4c1: In addition to statin - Zetia (ezetimibe) or generic ezetimibe - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar4c2",
    "Description": "A3ar4c2: Without a statin - Zetia (ezetimibe) or generic ezetimibe - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar5c1",
    "Description": "A3ar5c1: In addition to statin - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3ar5c2",
    "Description": "A3ar5c2: Without a statin - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, approximately what % of those LAST 100 [res PatientHoverover] received that therapy in addition to a statin vs. without a statin?",
    "Answer_Options": "NA",
    "ParentQuestion": "A3a"
  },
  {
    "Column": "A3br1c1",
    "Description": "A3br1c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Leqvio (inclisiran) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br1c2",
    "Description": "A3br1c2: AFTER trying another lipid-lowering therapy - Leqvio (inclisiran) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a statin did so",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br2c1",
    "Description": "A3br2c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Praluent (alirocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br2c2",
    "Description": "A3br2c2: AFTER trying another lipid-lowering therapy - Praluent (alirocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a statin did s",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br3c1",
    "Description": "A3br3c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Repatha (evolocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br3c2",
    "Description": "A3br3c2: AFTER trying another lipid-lowering therapy - Repatha (evolocumab) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy without a statin did so",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br4c1",
    "Description": "A3br4c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received tha",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br4c2",
    "Description": "A3br4c2: AFTER trying another lipid-lowering therapy - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] who received that therapy witho",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br5c1",
    "Description": "A3br5c1: BEFORE any other lipid-lowering therapy (i.e., first line) - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res Pati",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A3br5c2",
    "Description": "A3br5c2: AFTER trying another lipid-lowering therapy - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you prescribe without a statin, approximately what % of those [res PatientHoverover] w",
    "Answer_Options": "NA",
    "ParentQuestion": "A3b"
  },
  {
    "Column": "A4r1c1",
    "Description": "A4r1c1: Statin only (i.e., no additional therapy) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exer",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r2c1",
    "Description": "A4r2c1: Leqvio (inclisiran) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in comb",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r3c1",
    "Description": "A4r3c1: Praluent (alirocumab) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in co",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r4c1",
    "Description": "A4r4c1: Repatha (evolocumab) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in com",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r5c1",
    "Description": "A4r5c1: Zetia (ezetimibe) or generic ezetimibe - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercis",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r6c1",
    "Description": "A4r6c1: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r7c1",
    "Description": "A4r7c1: Other - LAST 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with o",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r1c2",
    "Description": "A4r1c2: Statin only (i.e., no additional therapy) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exer",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r2c2",
    "Description": "A4r2c2: Leqvio (inclisiran) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in comb",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r3c2",
    "Description": "A4r3c2: Praluent (alirocumab) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in co",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r4c2",
    "Description": "A4r4c2: Repatha (evolocumab) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in com",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r5c2",
    "Description": "A4r5c2: Zetia (ezetimibe) or generic ezetimibe - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercis",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r6c2",
    "Description": "A4r6c2: Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4r7c2",
    "Description": "A4r7c2: Other - NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Now please assume that the FDA decides that all PCSK9is (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with o",
    "Answer_Options": "NA",
    "ParentQuestion": "A4"
  },
  {
    "Column": "A4ar1c1",
    "Description": "A4ar1c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Leqvio (inclisiran) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar1c2",
    "Description": "A4ar1c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Leqvio (inclisiran) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar2c1",
    "Description": "A4ar2c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Praluent (alirocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. withou",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar2c2",
    "Description": "A4ar2c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Praluent (alirocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. withou",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar3c1",
    "Description": "A4ar3c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Repatha (evolocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar3c2",
    "Description": "A4ar3c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Repatha (evolocumab) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a statin vs. without",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar4c1",
    "Description": "A4ar4c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Zetia (ezetimibe) or generic ezetimibe - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar4c2",
    "Description": "A4ar4c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Zetia (ezetimibe) or generic ezetimibe - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe that therapy in addition to a",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar5c1",
    "Description": "A4ar5c1: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4ar5c2",
    "Description": "A4ar5c2: NEXT 100 [res PatientHoverover2] with Uncontrolled LDL-C - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment, for approximately what % of those NEXT 100 [res PatientHoverover] would you expect to prescribe",
    "Answer_Options": "NA",
    "ParentQuestion": "A4a"
  },
  {
    "Column": "A4br1c1",
    "Description": "A4br1c1: Next treatment allocation - Leqvio (inclisiran) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin woul",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br1c2",
    "Description": "A4br1c2: Next treatment allocation - Leqvio (inclisiran) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin woul",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br2c1",
    "Description": "A4br2c1: Next treatment allocation - Praluent (alirocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wo",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br2c2",
    "Description": "A4br2c2: Next treatment allocation - Praluent (alirocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wo",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br3c1",
    "Description": "A4br3c1: Next treatment allocation - Repatha (evolocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wou",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br3c2",
    "Description": "A4br3c2: Next treatment allocation - Repatha (evolocumab) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy without a statin wou",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br4c1",
    "Description": "A4br4c1: Next treatment allocation - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy wi",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br4c2",
    "Description": "A4br4c2: Next treatment allocation - Zetia (ezetimibe) or generic ezetimibe - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who would receive that therapy wi",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br5c1",
    "Description": "A4br5c1: Next treatment allocation - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A4br5c2",
    "Description": "A4br5c2: Next treatment allocation - Nexletol (bempedoic acid) or Nexlizet (bempedoic acid and ezetimibe) - For each treatment you just indicated that you would expect to prescribe without a statin, approximately what % of those [res PatientHoverover] who",
    "Answer_Options": "NA",
    "ParentQuestion": "A4b"
  },
  {
    "Column": "A5",
    "Description": "A5: How quickly might you expect to change your prescribing of PCSK9 inhibitors based on this indication change?",
    "Answer_Options": "1=Within 3 months,2=4-6 months,3=7-12 months,4=Over a year"
  },
  {
    "Column": "A6r1",
    "Description": "A6r1: Start statin first, add/switch to ezetimibe or Nexletol/Nexlizet if needed - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or i",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r2",
    "Description": "A6r2: Start statin and ezetimibe or Nexletol/Nexlizet at the same time - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combinat",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r3",
    "Description": "A6r3: Start ezetimibe or Nexletol/Nexlizet, no statin - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LD",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r4",
    "Description": "A6r4: Start statin first, add/switch to PCSK9i if needed - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r5",
    "Description": "A6r5: Start statin and PCSK9i at the same time - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LDL-C-low",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r6",
    "Description": "A6r6: Start PCSK9i, no statin - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LDL-C-lowering therapies,",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r7",
    "Description": "A6r7: Start statin first, add/switch to ezetimibe or Nexletol/Nexlizet if needed, add/switch to PCSK9i if needed after that - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A6r8",
    "Description": "A6r8: Other - Again, please assume that the FDA decides that all PCSK9 inhibitors (Repatha, Praluent, Leqvio) will now be indicated for use as an adjunct to diet and exercise, alone or in combination with other LDL-C-lowering therapies, in adults with pri",
    "Answer_Options": "NA",
    "ParentQuestion": "A6"
  },
  {
    "Column": "A7r1",
    "Description": "A7r1: Makes PCSK9s easier to get covered by insurance / get patients on the medication - How might being able to use PCKS9 inhibitors indicated for use with or without statin therapy impact your perceptions and/or prescribing?",
    "Answer_Options": "0=NO TO: Makes PCSK9s easier to get covered by insurance / get patients on the medication,1=Makes PCSK9s easier to get covered by insurance / get patients on the medication",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r2",
    "Description": "A7r2: Offers an option to patients who can’t or won’t take a statin - How might being able to use PCKS9 inhibitors indicated for use with or without statin therapy impact your perceptions and/or prescribing?",
    "Answer_Options": "0=NO TO: Offers an option to patients who can’t or won’t take a statin,1=Offers an option to patients who can’t or won’t take a statin",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r3",
    "Description": "A7r3: Enables me to use PCSK9s sooner for patients - How might being able to use PCKS9 inhibitors indicated for use with or without statin therapy impact your perceptions and/or prescribing?",
    "Answer_Options": "0=NO TO: Enables me to use PCSK9s sooner for patients,1=Enables me to use PCSK9s sooner for patients",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r4",
    "Description": "A7r4: Allows me to better customize treatment plans for patients - How might being able to use PCKS9 inhibitors indicated for use with or without statin therapy impact your perceptions and/or prescribing?",
    "Answer_Options": "0=NO TO: Allows me to better customize treatment plans for patients,1=Allows me to better customize treatment plans for patients",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r5",
    "Description": "A7r5: Other (Specify) - How might being able to use PCKS9 inhibitors indicated for use with or without statin therapy impact your perceptions and/or prescribing?",
    "Answer_Options": "0=NO TO: Other (Specify),1=Other (Specify)",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A7r5oe",
    "Description": "A7r5oe: How might being able to use PCKS9 inhibitors indicated for use with or without statin therapy impact your perceptions and/or prescribing? - Other (Specify)",
    "Answer_Options": "NA",
    "ParentQuestion": "A7"
  },
  {
    "Column": "A8r1c1",
    "Description": "A8r1c1: Repatha - With established CVD - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r1c2",
    "Description": "A8r1c2: Praluent - With established CVD - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r1c3",
    "Description": "A8r1c3: Leqvio - With established CVD - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r2c1",
    "Description": "A8r2c1: Repatha - With no history of CV events and at high-risk - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r2c2",
    "Description": "A8r2c2: Praluent - With no history of CV events and at high-risk - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r2c3",
    "Description": "A8r2c3: Leqvio - With no history of CV events and at high-risk - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r3c1",
    "Description": "A8r3c1: Repatha - With no history of CV events and at low-to-medium risk - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r3c2",
    "Description": "A8r3c2: Praluent - With no history of CV events and at low-to-medium risk - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r3c3",
    "Description": "A8r3c3: Leqvio - With no history of CV events and at low-to-medium risk - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r4c1",
    "Description": "A8r4c1: Repatha - Who are not known to be compliant on statins - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r4c2",
    "Description": "A8r4c2: Praluent - Who are not known to be compliant on statins - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r4c3",
    "Description": "A8r4c3: Leqvio - Who are not known to be compliant on statins - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r5c1",
    "Description": "A8r5c1: Repatha - Who are intolerant of statins - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r5c2",
    "Description": "A8r5c2: Praluent - Who are intolerant of statins - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A8r5c3",
    "Description": "A8r5c3: Leqvio - Who are intolerant of statins - For each patient situation, how likely would you be to prescribe each of the following therapies alone (i.e., without a statin, ezetimibe or Nexletol/Nexlizet)?",
    "Answer_Options": "1=Not at all likely,2=Slightly likely,3=Somewhat likely,4=Very likely,5=Extremely likely",
    "ParentQuestion": "A8"
  },
  {
    "Column": "A9c1",
    "Description": "A9c1: Repatha - To what extent have you encountered any issues with coverage, approvals, cost, etc. for using each of the following without a statin today?",
    "Answer_Options": "1=No issues,2=Some issues,3=Significant issues,4=Haven’t prescribed without a statin",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9c2",
    "Description": "A9c2: Praluent - To what extent have you encountered any issues with coverage, approvals, cost, etc. for using each of the following without a statin today?",
    "Answer_Options": "1=No issues,2=Some issues,3=Significant issues,4=Haven’t prescribed without a statin",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A9c3",
    "Description": "A9c3: Leqvio - To what extent have you encountered any issues with coverage, approvals, cost, etc. for using each of the following without a statin today?",
    "Answer_Options": "1=No issues,2=Some issues,3=Significant issues,4=Haven’t prescribed without a statin",
    "ParentQuestion": "A9"
  },
  {
    "Column": "A10r1",
    "Description": "A10r1: Patient failed statins prior to starting PCSK9i - For what reasons are you using PCSK9 inhibitors without a statin today?",
    "Answer_Options": "0=NO TO: Patient failed statins prior to starting PCSK9i,1=Patient failed statins prior to starting PCSK9i",
    "ParentQuestion": "A10"
  },
  {
    "Column": "A10r2",
    "Description": "A10r2: Patient is statin intolerant - For what reasons are you using PCSK9 inhibitors without a statin today?",
    "Answer_Options": "0=NO TO: Patient is statin intolerant,1=Patient is statin intolerant",
    "ParentQuestion": "A10"
  },
  {
    "Column": "A10r3",
    "Description": "A10r3: Patient refused statins - For what reasons are you using PCSK9 inhibitors without a statin today?",
    "Answer_Options": "0=NO TO: Patient refused statins,1=Patient refused statins",
    "ParentQuestion": "A10"
  },
  {
    "Column": "A10r4",
    "Description": "A10r4: Statins are contraindicated for patient - For what reasons are you using PCSK9 inhibitors without a statin today?",
    "Answer_Options": "0=NO TO: Statins are contraindicated for patient,1=Statins are contraindicated for patient",
    "ParentQuestion": "A10"
  },
  {
    "Column": "A10r5",
    "Description": "A10r5: Patient not or unlikely to be compliant on statins - For what reasons are you using PCSK9 inhibitors without a statin today?",
    "Answer_Options": "0=NO TO: Patient not or unlikely to be compliant on statins,1=Patient not or unlikely to be compliant on statins",
    "ParentQuestion": "A10"
  },
  {
    "Column": "A10r6",
    "Description": "A10r6: Haven’t prescribed PCSK9s without a statin - For what reasons are you using PCSK9 inhibitors without a statin today?",
    "Answer_Options": "0=NO TO: Haven’t prescribed PCSK9s without a statin,1=Haven’t prescribed PCSK9s without a statin",
    "ParentQuestion": "A10"
  },
  {
    "Column": "B1r1",
    "Description": "B1r1: Not insured - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r2",
    "Description": "B1r2: Private insurance provided by employer / purchased in exchange - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r3",
    "Description": "B1r3: Traditional Medicare (Medicare Part B Fee for Service) - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r4",
    "Description": "B1r4: Traditional Medicare with supplemental insurance - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r5",
    "Description": "B1r5: Private Medicare (Medicare Advantage / Part C managed through Private payer) - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r6",
    "Description": "B1r6: Medicaid - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r7",
    "Description": "B1r7: Veterans Administration (VA) - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B1r8",
    "Description": "B1r8: Other - What percentage of your current [res PatientHoverover] are covered by each type of insurance?",
    "Answer_Options": "NA",
    "ParentQuestion": "B1"
  },
  {
    "Column": "B2",
    "Description": "B2: What is the zip code of your main practice location?",
    "Answer_Options": "NA"
  },
  {
    "Column": "US_State",
    "Description": "US_State: US_State",
    "Answer_Options": "1=Alaska,2=Alabama,3=Arkansas,4=Arizona,5=California,6=Colorado,7=Connecticut,8=District of Columbia,9=Delaware,10=Florida,11=Georgia,12=Hawaii,13=Iowa,14=Idaho,15=Illinois,16=Indiana,17=Kansas,18=Kentucky,19=Louisiana,20=Massachusetts,21=Maryland,22=Maine,23=Michigan,24=Minnesota,25=Missouri,26=Mississippi,27=Montana,28=North Carolina,29=North Dakota,30=Nebraska,31=New Hampshire,32=New Jersey,33=New Mexico,34=Nevada,35=New York,36=Ohio,37=Oklahoma,38=Oregon,39=Pennsylvania,40=Rhode Island,41=South Carolina,42=South Dakota,43=Tennessee,44=Texas,45=Utah,46=Virginia,47=Vermont,48=Washington,49=Wisconsin,50=West Virginia,51=Wyoming,52=Other,53=Invalid State"
  },
  {
    "Column": "Region",
    "Description": "Region: Region",
    "Answer_Options": "1=Northeast,2=South,3=Midwest,4=West,5=Other,6=Invalid Region"
  },
  {
    "Column": "B3",
    "Description": "B3: Which of the following best describes where your primary practice is located?",
    "Answer_Options": "1=Urban,2=Suburban,3=Rural"
  },
  {
    "Column": "B4",
    "Description": "B4: How many physicians are in your practice?",
    "Answer_Options": "NA"
  },
  {
    "Column": "B5r1",
    "Description": "B5r1: Internal Medicine - How would you describe your specialty/training?",
    "Answer_Options": "0=NO TO: Internal Medicine,1=Internal Medicine",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r2",
    "Description": "B5r2: General Practitioner - How would you describe your specialty/training?",
    "Answer_Options": "0=NO TO: General Practitioner,1=General Practitioner",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r3",
    "Description": "B5r3: Primary Care - How would you describe your specialty/training?",
    "Answer_Options": "0=NO TO: Primary Care,1=Primary Care",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r4",
    "Description": "B5r4: Family Practice - How would you describe your specialty/training?",
    "Answer_Options": "0=NO TO: Family Practice,1=Family Practice",
    "ParentQuestion": "B5"
  },
  {
    "Column": "B5r5",
    "Description": "B5r5: Doctor of Osteopathic Medicine (DO) - How would you describe your specialty/training?",
    "Answer_Options": "0=NO TO: Doctor of Osteopathic Medicine (DO),1=Doctor of Osteopathic Medicine (DO)",
    "ParentQuestion": "B5"
  },
  {
    "Column": "QCONSENT",
    "Description": "QCONSENT: If you would be willing to participate in future research to further elaborate on the responses from this survey, please indicate below:",
    "Answer_Options": "1=Yes, I would be willing to participate in a follow-up interview for additional compensation,2=No, I am not interested in participating in a follow-up interview for additional compensation"
  },
  {
    "Column": "qtime",
    "Description": "qtime: Total Interview Time",
    "Answer_Options": "NA"
  },
  {
    "Column": "IMS_NUM",
    "Description": "IMS_NUM: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "NPI_NUM",
    "Description": "NPI_NUM: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "FULL_NM",
    "Description": "FULL_NM: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "DEG_TITLE",
    "Description": "DEG_TITLE: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "STATE",
    "Description": "STATE: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "ZIP_CD",
    "Description": "ZIP_CD: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_CD",
    "Description": "SPEC_CD: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_DESC",
    "Description": "SPEC_DESC: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_GRP_CD",
    "Description": "SPEC_GRP_CD: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SPEC_GRP_DESC",
    "Description": "SPEC_GRP_DESC: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "LEQ_TIER",
    "Description": "LEQ_TIER: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "PSCK9_DECILE",
    "Description": "PSCK9_DECILE: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SITE_ORG_ID",
    "Description": "SITE_ORG_ID: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SITE_ORG_NAME",
    "Description": "SITE_ORG_NAME: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "FINAL_FACILITY_TIER",
    "Description": "FINAL_FACILITY_TIER: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SOC_ID",
    "Description": "SOC_ID: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "SOC_Name",
    "Description": "SOC_Name: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "FINAL_SOC_TIER",
    "Description": "FINAL_SOC_TIER: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "x834_Flag",
    "Description": "x834_Flag: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "REGION_dupe1",
    "Description": "REGION_dupe1: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "DIVISION",
    "Description": "DIVISION: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "LEQ_C3M",
    "Description": "LEQ_C3M: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "LEQ_C6M",
    "Description": "LEQ_C6M: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "LEQ_C9M",
    "Description": "LEQ_C9M: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "LEQ_C12M",
    "Description": "LEQ_C12M: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "BUY_BILL_FLAG",
    "Description": "BUY_BILL_FLAG: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "ASOC_FLAG",
    "Description": "ASOC_FLAG: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "Procedure_Deciles",
    "Description": "Procedure_Deciles: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "Segment",
    "Description": "Segment: Captured variable",
    "Answer_Options": "NA"
  },
  {
    "Column": "AAID",
    "Description": "AAID: Captured variable",
    "Answer_Options": "NA"
  }
]